help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herbst, R. S.
Right arrow Articles by Kies, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herbst, R. S.
Right arrow Articles by Kies, M. S.
The Oncologist, Vol. 7, Suppl 4, 9-15, August 15, 2002
© 2002 AlphaMed Press

ZD1839 (IressaTM) in Non-Small Cell Lung Cancer

Roy S. Herbst, Merrill S. Kies

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Correspondence: Roy S. Herbst, M.D., M.D. Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd., Box 432, Houston, Texas 77030, USA. Telephone: 713-792-6363; Fax: 713-796-8655; e-mail: rherbst{at}mail.mdanderson.org

Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less toxicity than is associated with conventional cytotoxic chemotherapy. The epidermal growth factor receptor (EGFR) is recognized as a potentially useful target, and the small molecule, orally active EGFR-tyrosine kinase inhibitor ZD1839 (IressaTM) is currently the furthest along in clinical development of the anti-EGFR agents. This review summarizes the currently available clinical data on the use of ZD1839 in the treatment of NSCLC.

Key Words. ZD1839 (IressaTM) • NSCLC • Phase I • Phase II • Phase III




This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
B. C. Beehler, P. G. Sleph, L. Benmassaoud, and G. J. Grover
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Experimental Biology and Medicine, March 1, 2006; 231(3): 335 - 341.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C Festuccia, P Muzi, D Millimaggi, L Biordi, G L Gravina, S Speca, A Angelucci, V Dolo, C Vicentini, and M Bologna
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines
Endocr. Relat. Cancer, December 1, 2005; 12(4): 983 - 998.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A.L. Hamilton, J.P. Eder, A.C. Pavlick, J.W. Clark, L. Liebes, R. Garcia-Carbonero, A. Chachoua, D.P. Ryan, V. Soma, K. Farrell, et al.
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
J. Clin. Oncol., September 1, 2005; 23(25): 6107 - 6116.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson
Proteasome inhibitor therapy in multiple myeloma
Mol. Cancer Ther., April 1, 2005; 4(4): 686 - 692.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
F. Peiretti, M. Canault, D. Bernot, B. Bonardo, P. Deprez-Beauclair, I. Juhan-Vague, and G. Nalbone
Proteasome inhibition activates the transport and the ectodomain shedding of TNF-{alpha} receptors in human endothelial cells
J. Cell Sci., March 1, 2005; 118(5): 1061 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Demaria, F. R. Santori, B. Ng, L. Liebes, S. C. Formenti, and S. Vukmanovic
Select forms of tumor cell apoptosis induce dendritic cell maturation
J. Leukoc. Biol., March 1, 2005; 77(3): 361 - 368.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. V. Rajkumar, P. G. Richardson, T. Hideshima, and K. C. Anderson
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
J. Clin. Oncol., January 20, 2005; 23(3): 630 - 639.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. De Pas, G. Pelosi, F. de Braud, G. Veronesi, G. Curigliano, M. E. Leon, R. Danesi, C. Noberasco, M. d'Aiuto, G. Catalano, et al.
Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare
J. Clin. Oncol., December 15, 2004; 22(24): 4966 - 4970.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, and R I Nicholson
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
Endocr. Relat. Cancer, December 1, 2004; 11(4): 793 - 814.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Blaney, M. Bernstein, K. Neville, J. Ginsberg, B. Kitchen, T. Horton, S. L. Berg, M. Krailo, and P. C. Adamson
Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015)
J. Clin. Oncol., December 1, 2004; 22(23): 4804 - 4809.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Sweeney, L. Li, R. Shanmugam, P. Bhat-Nakshatri, V. Jayaprakasan, L. A. Baldridge, T. Gardner, M. Smith, H. Nakshatri, and L. Cheng
Nuclear Factor-{kappa}B Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate
Clin. Cancer Res., August 15, 2004; 10(16): 5501 - 5507.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. I. Amiri, L. W. Horton, B. J. LaFleur, J. A. Sosman, and A. Richmond
Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition: Implication for Bortezomib (VELCADE, PS-341) as a Therapeutic Agent for Malignant Melanoma
Cancer Res., July 15, 2004; 64(14): 4912 - 4918.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. F. Bross, R. Kane, A. T. Farrell, S. Abraham, K. Benson, M. E. Brower, S. Bradley, J. V. Gobburu, A. Goheer, S.-L. Lee, et al.
Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma
Clin. Cancer Res., June 15, 2004; 10(12): 3954 - 3964.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, J. S. Isaacs, K. S. Bisht, D. Gius, and L. Neckers
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity
Mol. Cancer Ther., May 1, 2004; 3(5): 551 - 566.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Q. Wang, T. Liu, Y. Fang, S. Xie, X. Huang, R. Mahmood, G. Ramaswamy, K. M. Sakamoto, Z. Darzynkiewicz, M. Xu, et al.
BUBR1 deficiency results in abnormal megakaryopoiesis
Blood, February 15, 2004; 103(4): 1278 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-F. Zhang, A. Tomida, R. Koshimizu, Y. Ogiso, S. Lei, and T. Tsuruo
Cullin 3 Promotes Proteasomal Degradation of the Topoisomerase I-DNA Covalent Complex
Cancer Res., February 1, 2004; 64(3): 1114 - 1121.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Laurent, S. de Bouard, J.-S. Guillamo, C. Christov, R. Zini, H. Jouault, P. Andre, V. Lotteau, and M. Peschanski
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo
Mol. Cancer Ther., February 1, 2004; 3(2): 129 - 136.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
X. Wang, N. Adhikari, Q. Li, Z. Guan, and J. L. Hall
The Role of {beta}-Transducin Repeat-Containing Protein ({beta}-TrCP) in the Regulation of NF-{kappa}B in Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 85 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Onn, A. M. Correa, M. Gilcrease, T. Isobe, E. Massarelli, C. D. Bucana, M. S. O'Reilly, W. K. Hong, I. J. Fidler, J. B. Putnam, et al.
Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Clin. Cancer Res., January 1, 2004; 10(1): 136 - 143.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. L Stanford and S. D Zondor
Bortezomib Treatment for Multiple Myeloma
Ann. Pharmacother., December 1, 2003; 37(12): 1825 - 1830.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. Y Liu and S. Seen
Gefitinib Therapy for Advanced Non-Small-Cell Lung Cancer
Ann. Pharmacother., November 1, 2003; 37(11): 1644 - 1653.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Luo, J. Zhang, C. Cheung, A. Suarez, B. M. McManus, and D. Yang
Proteasome Inhibition Reduces Coxsackievirus B3 Replication in Murine Cardiomyocytes
Am. J. Pathol., August 1, 2003; 163(2): 381 - 385.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2002 by AlphaMed Press.